Interventional, Randomized, Double-blind, Crossover, Placebo-controlled, Multiple-dose Lu AG06466 Phase 1 B Study in Patients With Focal Epilepsy Using EEG and PSG to Investigate Its Pharmacodynamic Effects on Prolonged Period of Inter- Icterical Spikes, Sleep and Neuroinflammation
Latest Information Update: 05 Sep 2022
At a glance
- Drugs Elcubragistat (Primary)
- Indications Partial epilepsies
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Lundbeck A/S
- 31 Aug 2022 Status changed from recruiting to discontinued.
- 15 Jun 2022 Planned primary completion date changed from 7 Jun 2023 to 1 Jun 2023.
- 05 May 2022 Planned End Date changed from 6 Nov 2022 to 7 Jun 2023.